Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this ...

Merck says some patents for its top-selling cancer drug, Keytruda, may be extended through 2029.

Armed with what CEO Robert Davis called the “broadest and widest pipeline we’ve had in years,” Merck is preparing for its ...

Merck’s stock falls as the full-year revenue and profit outlooks were below expectations.

Merck (NYSE:MRK) has invested $30 million for nearly a 10% stake in Eikon Therapeutics as Eikon moves toward an IPO. The ...

Merck topped Q4 earnings and revenue estimates, helped by Keytruda and animal health growth, but its 2026 earnings and sales guidance came in below Wall Street expectations.

Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s recent game plan. Cramer noted that he likes the stock, as ...

Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open. Wall Street expects earnings of $2.01 per share on revenue of $16.12 billion, representing 3.1% year-over-year growth ...

Merck reported revenue for the fourth quarter was $16.4 billion, an increase of 5% over the fourth quarter of 2024. For the ...

Merck & Co anticipates lower sales by 2026 due to patent expirations on key medications, including the diabetes drug Januvia.

In its 2025 full year and fourth-quarter earnings call, Merck executives touted the merits of recent deals and what CEO ...

For full-year 2025, Merck reported worldwide sales of $65B, up 1% Y/Y, or 2% excluding FX, while adjusted EPS totaled $8.98. Analysts had projected EPS of $8.94 for 2025 on revenue of $64.78B.